Results 151 to 160 of about 4,251 (181)

Acalabrutinib: First Global Approval

Drugs, 2017
Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence®) for the treatment of various haematological and solid malignancies. The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and ...
Anthony, Markham, Sohita, Dhillon
openaire   +2 more sources

Acalabrutinib

Reactions Weekly, 2021
openaire   +2 more sources

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib

OncoTargets and Therapy, 2021
Cândida Vitale, Alessandra Ferrajoli
exaly  

A validated chiral chromatographic method for the enantiomeric separation of acalabrutinib

Chirality, 2022
V V S Prasanna Kumari Rayala, Srinivasu Gunnam, Roshan M Borkar   +2 more
exaly  

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach

British Journal of Clinical Pharmacology, 2022
Helena Edlund, Karthick Vishwanathan, Shringi Sharma   +2 more
exaly  

EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

Oncologist, 2021
Julio Delgado, Harald Enzmann, Delgado Julio   +2 more
exaly  

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Lancet, The, 2020
Jeff P Sharman, Miklós Egyed, Wojciech Jurczak   +2 more
exaly  

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

Clinical Pharmacology in Drug Development, 2022
Veerendra Munugalavadla
exaly  

<p>Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data</p>

Cancer Management and Research, 2020
Krista M Isaac, Anthony R Mato
exaly  

Acalabrutinib (Calquence)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Calquence in combination with venetoclax be reimbursed by public drug plans for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) if certain conditions are met. The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that Calquence in ...
openaire   +1 more source